How Will Aducanumab Approval Impact AD Research?

Alzheimer’s Disease Neuroimaging Initiative (ADNI)

doi:10.14283/jpad.2021.46

How Will Aducanumab Approval Impact AD Research?

Alzheimer’s Disease Neuroimaging Initiative (ADNI)

Research output: Contribution to journal › Editorial › peer-review

Original language	English (US)
Pages (from-to)	391-392
Number of pages	2
Journal	The journal of prevention of Alzheimer's disease
Volume	8
Issue number	4
DOIs	https://doi.org/10.14283/jpad.2021.46
State	Published - Sep 2021

ASJC Scopus subject areas

Clinical Neurology
Psychiatry and Mental health

Access to Document

10.14283/jpad.2021.46

Cite this

@article{b9731df2e78d457693d4bc61a3d92def,

title = "How Will Aducanumab Approval Impact AD Research?",

author = "{Alzheimer{\textquoteright}s Disease Neuroimaging Initiative (ADNI)} and Weiner, {Michael W.} and Aisen, {P. S.} and Beckett, {L. A.} and Green, {R. C.} and W. Jagust and Morris, {J. C.} and O. Okonkwo and Perrin, {R. J.} and Petersen, {R. C.} and {Rivera Mindt}, M. and Saykin, {A. J.} and Shaw, {L. M.} and Toga, {A. W.} and Trojanowski, {J. Q.}",

note = "Funding Information: Disclosures: Dr. Aisen{\textquoteright}s work is supported by research agreements with Lilly and Eisai and research grants from NIA and the Alzheimer{\textquoteright}s Association; he receives consulting fees from Biogen, Roche, Merck, Abbvie, Immunobrain Checkpoint Rainbow Medical and Shionogi. Dr. Beckett is supported by NIH grants U01AG024904, R01AG062517, and B639943. Dr. Green is supported by NIH grants AG024904, AG047866, HG009922, HL143295, OD026553, TR003201, HG008685 and the Franca Sozzani Fund. Dr. Green has no financial interests in any pharmaceutical companies.: Dr. Jagust receives grant funding from the NIH/NIA, the Rainwater Foundation, and Roche/Genentech. He serves as a consultant to Bioclinica, Biogen, and CuraSen. Dr. Morris is funded by NIH grants P30 AG066444; P01AG003991; P01AG026276; U19 AG032438; and U19 AG024904. Neither Dr. Morris nor his family owns stock or has equity interest (outside of mutual funds or other externally directed accounts) in any pharmaceutical or biotechnology company. Dr. Perrin{\textquoteright}s laboratory provides autopsy/tissue donationservices for local participants enrolled in Biogen{\textquoteright}s clinical trials of ALS treatments. Dr. Petersen receives funding from NIH grants P30 AG0620677, U01 AG006786, U01 AG024904 and U24 AG057437, is a consultant for Roche, Merck, Biogen, and Eisai, and serves on the Data Safety Monitoring Board of Genentech. Dr. Rivera Mindt{\textquoteright}s work is supported by NIH/NIA grants (R01AG065110, R13AG071313, SC3GM141996, R01AG066471-01A1, and U19AG024904), the Alzheimer{\textquoteright}s Association (AARGD-16-446038), and the Genentech Health Equity Fund (G-89294). Dr. Saykin is supported by multiple NIH grants (P30 AG010133, P30 AG072976, R01 AG019771, R01 AG057739, U01 AG024904, R01 LM013463, R01 AG068193, T32 AG071444, and U01 AG068057). He has also received support from Avid Radiopharmaceuticals, a subsidiary of Eli Lilly (in kind contribution of PET tracer precursor); Bayer Oncology (Scientific Advisory Board); and Springer-Nature Publishing (Editorial Office Support as Editor-in-Chief, Brain Imaging and Behavior). Dr. Shaw is supported by NIH/NIA grants, ADI biomarker Core, Penn ADRC Biomarker Core, the M.J. Fox Foundations, and Roche IIS AD biomarker studies. Dr. Shaw receives honoraria from the Biogen teaching program on fluid biomarkers, and the Fujirebio teaching program on biomarkers. Drs. Beckett, Okonkwo, Rivera-Mindt, Toga Trojanowski have no conflicts to report.",

year = "2021",

month = sep,

doi = "10.14283/jpad.2021.46",

language = "English (US)",

volume = "8",

pages = "391--392",

journal = "The journal of prevention of Alzheimer's disease",

issn = "2426-0266",